BioCrine AB
BioCrine AB is a research-driven company focused on developing innovative treatments for diabetes and other diseases through advanced technology and scientific research. Their mission is to find effective treatments for diabetes by commercializing patented research programs and utilizing unique technological platforms like InSight Technology.
Industries
Nr. of Employees
small (1-50)
Patents
Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis
US-10695425-B2
View Details
Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis
US-10695425-B2
View DetailsProducts
Patented research program: serum factor (apoCIII)
A research program focused on apolipoprotein CIII as a serum factor implicated in metabolic derangements and diabetes, maintained as a patented program for development or licensing.
Patented research program: insulin receptor isoforms
A program exploring insulin receptor isoforms as potential therapeutic targets for diabetes, retained as a patent-ready research asset.
Patented research program: calcium channel subunit targets
A research program identifying and developing calcium channel subunits (e.g., beta3) as intervention points to reverse diabetic phenotypes in preclinical studies.
Patented research program: inositol polyphosphate signaling in insulin release
A program focused on inositol polyphosphates and pyrophosphates as regulators of insulin secretion, positioned for therapeutic exploration.
Patented research program: serum factor (apoCIII)
A research program focused on apolipoprotein CIII as a serum factor implicated in metabolic derangements and diabetes, maintained as a patented program for development or licensing.
Patented research program: insulin receptor isoforms
A program exploring insulin receptor isoforms as potential therapeutic targets for diabetes, retained as a patent-ready research asset.
Patented research program: calcium channel subunit targets
A research program identifying and developing calcium channel subunits (e.g., beta3) as intervention points to reverse diabetic phenotypes in preclinical studies.
Patented research program: inositol polyphosphate signaling in insulin release
A program focused on inositol polyphosphates and pyrophosphates as regulators of insulin secretion, positioned for therapeutic exploration.
Services
Commercialization-focused activities around patented research programs in diabetes-related targets and mechanisms, intended for licensing or development partnerships.
Collaboration or partnership opportunities to apply ocular-window imaging platforms, intravital imaging techniques, and related translational methods for preclinical and early clinical research.
Commercialization-focused activities around patented research programs in diabetes-related targets and mechanisms, intended for licensing or development partnerships.
Collaboration or partnership opportunities to apply ocular-window imaging platforms, intravital imaging techniques, and related translational methods for preclinical and early clinical research.
Expertise Areas
- Translational research for cell-based therapies
- Intravital and optical imaging for live-cell observation
- Diabetes therapeutic target discovery
- Preclinical transplantation models and immunomodulation
Key Technologies
- Intravital microscopy and optical imaging
- Anterior chamber ocular window transplantation technique
- 3D intravital imaging
- Microscale implantable ocular devices
News & Updates
Shareholders' annual meeting on June 17, 2024, at Redeye AB, Stockholm.
Shareholders' annual meeting on June 16, 2023, at Mäster Samuelsgatan 42, Stockholm.
A list of scientific publications by Professor P-O Berggren and his research group since 2013.
Development of a method to study liver function and disease without invasive procedures, published in Nature Communications.
A novel technique to monitor intraocular pressure in the context of islet transplantation.
Received major distinctions including the Wallenberg Scholars, The Novo Nordisk Foundation Advanced Grant, and Kroc Lecture.
Shareholders' annual meeting on June 17, 2024, at Redeye AB, Stockholm.
Shareholders' annual meeting on June 16, 2023, at Mäster Samuelsgatan 42, Stockholm.
A list of scientific publications by Professor P-O Berggren and his research group since 2013.
Development of a method to study liver function and disease without invasive procedures, published in Nature Communications.
A novel technique to monitor intraocular pressure in the context of islet transplantation.
Received major distinctions including the Wallenberg Scholars, The Novo Nordisk Foundation Advanced Grant, and Kroc Lecture.